摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-(3,5-dichloropyridin-4-yloxy)benzenamine | 890664-90-1

中文名称
——
中文别名
——
英文名称
4-(3,5-dichloropyridin-4-yloxy)benzenamine
英文别名
4-(3,5-Dichloro-pyridin-4-yloxy)-phenylamine;4-(3,5-dichloropyridin-4-yl)oxyaniline
4-(3,5-dichloropyridin-4-yloxy)benzenamine化学式
CAS
890664-90-1
化学式
C11H8Cl2N2O
mdl
——
分子量
255.103
InChiKey
KGDXOLFZWRSQIQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3
  • 重原子数:
    16
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    48.1
  • 氢给体数:
    1
  • 氢受体数:
    3

反应信息

点击查看最新优质反应信息

文献信息

  • Inhibitors of protein kinases
    申请人:Locus Pharmaceuticals, Inc.
    公开号:US07612200B2
    公开(公告)日:2009-11-03
    The present invention is directed to a compound having the formula wherein R1, R2, R3, R4, G, and Q are defined herein. The compounds of the present invention are useful as inhibitors of protein kinases. The present invention is also directed to compositions comprising a compound according to the above formula. The present invention is also directed to compounds that stabilize the open conformation of a protein kinase, a crystallized protein kinase in the open conformation, and uses thereof. The compounds and compositions described herein are useful for treating and preventing an inflammatory condition or disease.
    本发明涉及一种化合物,其具有以下结构式,其中R1、R2、R3、R4、G和Q在此被定义。本发明的化合物可用作蛋白激酶的抑制剂。本发明还涉及包含上述结构式化合物的组合物。本发明还涉及稳定蛋白激酶开放构象的化合物、晶化蛋白激酶的开放构象以及其用途。本文所描述的化合物和组合物可用于治疗和预防炎症状况或疾病。
  • INHIBITORS OF PROTEIN KINASES
    申请人:Michelotti Enrique Luis
    公开号:US20090192307A1
    公开(公告)日:2009-07-30
    The present invention is directed to a compound having the formula wherein R 1 , R 2 , R 3 , R 4 , G, and Q are defined herein. The compounds of the present invention are useful as inhibitors of protein kinases. The present invention is also directed to compositions comprising a compound according to the above formula. The present invention is also directed to compounds that stabilize the open conformation of a protein kinase, a crystallized protein kinase in the open conformation, and uses thereof. The compounds and compositions described herein are useful for treating and preventing an inflammatory condition or disease.
    本发明涉及一种具有以下式子的化合物,其中R1、R2、R3、R4、G和Q如下所定义。本发明的化合物可用作蛋白激酶抑制剂。本发明还涉及包含上述式子中的化合物的组合物。本发明还涉及稳定蛋白激酶开放构象的化合物,以及开放构象的结晶蛋白激酶和其用途。本发明所描述的化合物和组合物可用于治疗和预防炎症性疾病或病症。
  • US7612200B2
    申请人:——
    公开号:US7612200B2
    公开(公告)日:2009-11-03
  • [EN] INHIBITORS OF PROTEIN KINASES<br/>[FR] INHIBITEURS DE PROTEINES KINASES
    申请人:LOCUS PHARMACEUTICALS INC
    公开号:WO2006062984A2
    公开(公告)日:2006-06-15
    [EN] The present invention is directed to a compound having the formula (I) wherein R1, R2, R3, R4, G, and Q are defined herein. The compounds of the present invention are useful as inhibitors of protein kinases. The present invention is also directed to compositions comprising a compound according to the above formula. The present invention is also directed to compounds that stabilize the open conformation of a protein kinase, a crystallized protein kinase in the open conformation, and uses thereof. The compounds and compositions described herein are useful for treating and preventing an inflammatory condition or disease.
    [FR] L'invention concerne un composé de formule (I) dans laquelle R1, R2, R3, R4, G et Q sont tels que définis dans la description. Les composés selon l'invention sont utiles comme inhibiteurs de protéines kinases. L'invention concerne également des compositions renfermant un composé selon la formule susmentionnée. L'invention concerne, en outre, des composés stabilisant la conformation ouverte d'une protéine kinase, une protéine kinase cristallisée en conformation ouverte et l'utilisation de ceux-ci. Les composés et compositions selon l'invention sont utiles dans le traitement et la prévention d'un état ou d'une maladie inflammatoire.
  • WO2006/62984
    申请人:——
    公开号:——
    公开(公告)日:——
查看更多